Clear All
731 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Sotorasib Lumakras Multiple Chemotherapy RAS Inhibitor KRASG12C Yes 2021 In Use
J9272 Dostarlimab-gxly Jemperli 10mg Immunotherapy Checkpoint Inhibitor PD-1 No 2021 Jan 26, 2022 In Use
J1932 Lanreotide (Cipla) Lanreotide Acetate 1mg Hormonal Therapy Somatostatin Analog No 2021 Sep 27, 2022 In Use
J9247 Melphalan flufenamide Pepaxto 1mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2021 Sep 27, 2021 In Use
J9061 Amivantamab Rybrevant 2mg Immunotherapy Monoclonal Antibody EGFR, MET No 2021 Jan 26, 2022 In Use
NA Tepotinib Hydrochloride Tepmetko 225mg Chemotherapy Tyrosine Kinase Inhibitor MET Yes 2021 In Use
NA Dostarlimab Jemperli 50mg Immunotherapy Checkpoint Inhibitor PD-1 Yes 2021 In Use
J9063 Mirvetuximab soravtansine Elahere 1mg Immunotherapy Drug Antibody Conjugate FR-alpha, DM4 No 2022 Jul 11, 2023 In Use
J9296 Pemetrexed (Accord) Pemetrexed (Accord) 10mg Chemotherapy Antimetabolite Folic Acid Analog No 2022 Mar 17, 2023 In Use
J9294 Pemetrexed (Hospira) Pemetrexed (Hospira) 10mg Chemotherapy Antimetabolite Folic Acid Analog No 2022 Mar 17, 2023 In Use
J9274 Tebentafusp-tebn Kimmtrak 1mcg Immunotherapy T Cell Receptor (TCR) HLA-A*02:01 No 2022 Sep 27, 2022 In Use
C9095 Tebentafusp-tebn Kimmtrak 1mcg Immunotherapy T Cell Receptor (TCR) HLA-A*02:01 No 2022 Mar 25, 2022 Sep 27, 2022 No Longer Used
Q5130 Pegfilgrastim-pbbk Fylnetra 0.5mg Ancillary Therapy Immunostimulant Granulocyte colony stimulating factor No 2022 Mar 17, 2023 In Use
C9147 Tremelimumab-actl Imjudo 1mg Immunotherapy Monoclonal Antibody CTLA-4 No 2022 Mar 17, 2023 Jul 11, 2023 No Longer Used
J9059 Bendamustine (Baxter) Bendamustine (Baxter) 1mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2022 Jul 11, 2023 In Use
J9297 Pemetrexed (Sandoz) Pemetrexed (Sandoz) 10mg Chemotherapy Antimetabolite Folic Acid Analog No 2022 Mar 17, 2023 In Use
J9051 Bortezomib (Maia) Bortezomib 0.1mg Chemotherapy Proteasome Inhibitor 26S Yes 2022 Aug 28, 2023 In Use
J9322 Pemetrexed (Bluepoint) Pemetrexed (Bluepoint) 10mg Chemotherapy Antimetabolite Folic Acid Analog No 2022 Jul 11, 2023 In Use
J9314 Pemetrexed (Teva) Pemetrexed (Teva) 10mg Chemotherapy Antimetabolite Folic Acid Analog No 2022 Dec 21, 2022 In Use
J9046 Bortezomib (Dr Reddy) Bortezomib (Dr Reddy) 0.1mg Chemotherapy Proteasome Inhibitor 26S No 2022 Dec 21, 2022 In Use
J9052 Carmustine (Accord) Carmustine 100mg Chemotherapy Alkylating Agent Nitrosurea No 2022 Dec 7, 2023 In Use
Pacritinib Vonjo 100mg Chemotherapy Tyrosine Kinase Inhibitor JAK2, FLT3 Yes 2022 In Use
J9380 Teclistamab cqyv Tecvayli 0.5mg Immunotherapy Monoclonal Antibody BCMA, CD3 No 2022 Jul 11, 2023 In Use
J9049 Bortezomib (Hospira) Bortezomib (Hospira) 0.1mg Chemotherapy Proteasome Inhibitor 26S No 2022 Dec 21, 2022 In Use
J9350 Mosunetuzumab-axgb Lunsumio 1mg Immunotherapy Monoclonal Antibody CD20, CD3 No 2022 Jul 11, 2023 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.